myviralspiral3.com

Newark, DE (PRWeb) 19 December 2011

Fertility doctors Reproductive Associates of Delaware (RAD) is alarmed about the rising tide of failed in vitro fertilization (IVF) treatments that come in throughout the U.S. and the world, and recommend further analysis of a study of patients who do not follow IVF or IVF is unnecessary. They started a new pilot program called the game failed IVF, probation.

“IVF is an important and effective treatment for those who really need,” said Ronald F. Feinberg MD, PhD, a reproductive endocrinologist who has directed RAD IVF program since 1997. “But many women are not IVF, or perhaps not even need IVF, the underlying disease is not identified or treated well.”

some common diseases may block embryo implantation and pregnancy hurt your chances, including endometriosis, uterine polyps, uterine and diseased fallopian tubes. Pelvic adhesions can also restrict blood flow to the ovaries and interfere with normal development of eggs. Conducted before Cesare and other major features can often lead to adhesions, resulting in infertility. Numerous published studies have shown that minimally invasive, outpatient treatment by experienced surgeons perform hysteroscopy and laparoscopy will often increase fertility or to prevent infertility.

“Most women have abortions because of these problems, many IVF centers tend to be drawn from this information,” said Barbara A. McGuirk, MD, a reproductive endocrinologist and director of reproductive surgery RAD is a program since 1995. “When we do a detailed and thorough evaluation of the uterus, ovaries, fallopian tubes and pelvic structures to the present time, and treating diseases that cause infertility. Our approach includes professional 2-doc team, excellent anesthesia and surgery performed through a small opening in the skin that does not rate. “

Centers for Disease Control (CDC), there are many cases of female infertility “unexplained”. “Unexplained infertility in women is often unknown infertility,” said Dr. McGuirk, “and we believe that many women and children are shortchanged and premature damage to continue IVF treatment. Many of our patients who may have been pushed into IVF else actually able to for pregnancy at our center without IVF. “

work team is expected to fit in the pilot program will help assess the extent of the problem associated with unsuccessful IVF treatment and unnecessary. Their goal is to find patients who have been unsuccessful with IVF and non-RAD and had pre-existing conditions or to evaluate carefully treated. RAD team is particularly interested in the assessment of women before or after fertilization, which are marked with “unexplained infertility”.

As part of the matching program, previous treatment records carefully reviewed and those patients interested in the game will be well informed about the possibilities to increase the diagnosis and treatment. The results of the program will continue in some way. One future goal is to make a prospective study of the impact assessment corresponding to the results of fertility.

IVF results are presented and are issued by most U.S. clinics in collaboration with the CDC to the public to read. “Some of the CDC data misleading,” said Dr. Feinberg, “because it is very difficult to know what patients really need IVF compared to those who could benefit from non-IVF treatments. Patients who achieved a pregnancy after hysteroscopy and / or laparoscopy not included in the CDC data. “

of all IVF pregnancies achieved in Delaware, was 85% conceived in the mid-RAD is based on an analysis of the published CDC data. Many of these results and lower risk singleton pregnancy was directed to the appropriate models of care, resulting in work, including many patients who have failed IVF elsewhere. As more evidence of increased embryo in the womb an embryo is a blastocyst transfer RAD approach has consistently delivered many pregnant women, and one of the lowest Multiple pregnancy rates in the U.S.

RAD Group is also actively evaluating chromosomal abnormalities in the blastocysts that appear normal but are likely to lead to failed implantation or miscarriage. Performance and results of preimplantation genetic screening (PGS), are presented at national meetings in 2010 and 2011, American Society for Reproductive Medicine (ASRM).

Doctor RAD team has two other reproductive endocrinologists Dr. Adrienne Neithardt and Dr. George Kovalevsky and four doctors to advise patients on the three different locations in Wilmington Delaware, Dover, and the main office and IVF Center in Newark on the campus of Christiana Health System . Doctors also meet doctors and teachers work for Christiana Care obstetrics / gynecology residents and medical students to Jefferson.

###

Scottsdale, AZ (PRWeb) January 21, 2012

Quality Stocks invo would describe biomedicine, publicly traded medical device company focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. Lead company’s products, INVOcell is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development.

company news yesterday

INVO Bioscience announced that a national health surveillance agency (ANVISA) in Brazil INVOcell is approved for use as Class II devices, which makes the sale of INVOcell in the Brazilian market.

approval marks a significant milestone in the history INVOs, and opens the door for invo use one of the largest markets and a rapidly growing economy in the world.

consent in Brazil is a very important step in the success of INVOcell in support of country medical thought leaders like Dr. Coelho, Kathleen Karloff, Chief Executive Officer of INVO in a statement. Today’s announcement paves the way for more than 125 fertility centers in Brazil to start by offering infertile couples a safe and cost effective solution compared to conventional IVF. We look forward to working with EcoMed, distribution partner in Brazil, such as starting to encourage their sales and marketing.

ANVISA approval triggered by the end of the 40 patients clinical study conducted in Rio de Janeiro, Brazil, to establish the safety, effectiveness and comparative in vitro fertilization (IVF) measures INVOcell device.

trial results, coupled with the clinical results of the Colombian Fertility and Sterility Center (CECOLFES) in Colombia, were submitted to ANVISA to achieve registration and approval for the sale of INVOcell devices in Brazil.

INVOcell is CE Mark approved in Europe and Canada, and is also available in many Latin America. Karloff noted that if INVOcell can capture 5 percent of the market in Brazil, this could equate to more than $ 10 million in sales.

also listed several advantages INVOcell devices, including a reduced incidence of multiple pregnancies and the subsequent costs and complications, the relative cost advantages INVOcell procedure compared to conventional treatment and IVF pregnancies is comparable with conventional IVF treatment.

Quality Stocks

quality shares, based in Scottsdale, Arizona, is a free service that collects data from hundreds Small Cap and Micro-Cap online Investment Newsletters into one daily newsletter report. Quality Stocks is dedicated to helping public companies to make efforts for investor relations and connect subscribers with companies that have huge potential to succeed in the short and long term future.

To sign up for Quality Stocks Daily Newsletter, visit http://www.QualityStocks.net

to connect the quality of the stock through Facebook, visit http://Facebook.com/QualityStocksPage

to connect the quality of the stocks through Twitter is to find http://Twitter.com/QualityStocks

Please see disclaimer on every page of Quality Stocks: http://Disclaimer.QualityStocks.net

future statement:

This document may contain statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions regarding future events or future performance of the company. Readers are cautioned not to over-reliance on these statements, which are only predictions and speak only from the date hereof. Risks and uncertainties relating to the company and its business could cause the Company’s actual results to differ materially from those stated in any statement.

###

Related Pregnancy News